Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

May 25, 2015 5:43 PM ET


Company Overview of aTyr Pharma Inc.

Company Overview

aTyr Pharma, Inc. engages in the discovery and clinical development of protein based therapeutics for patients suffering from severe and rare diseases. The company is developing Resolaris, which is in Phase Ib/II clinical trials in adult patients with facioscapulohumeral muscular dystrophy, a rare genetic myopathy with an immune component. Its products pipeline also includes Resolaris for treatment of patients with early onset facioscapulohumeral muscular dystrophy, a rare genetic myopathy with an immune component and limb-girdle muscular dystrophies, as well as rare pulmonary diseases with an immune component. In addition, the company is developing iMod.Fc, a preclinical immuno-modulatory d...

3545 John Hopkins Court

Suite 250

San Diego, CA 92121

United States

Founded in 2005

49 Employees





Key Executives for aTyr Pharma Inc.

Executive Chairman and Chief Executive Officer
Age: 54
Total Annual Compensation: $410.0K
President and Chief Operating Officer
Age: 47
Total Annual Compensation: $319.7K
Chief Medical Officer
Age: 49
Total Annual Compensation: $265.2K
Compensation as of Fiscal Year 2014.

aTyr Pharma Inc. Key Developments

aTyr Pharma Inc.(NasdaqGS:LIFE) added to NASDAQ Composite Index

aTyr Pharma Inc. has been added to Nasdaq Composite Index.

aTyr Pharma Appoints Marcy Graham as Vice President, Investor Relations and Corporate Communications

aTyr Pharma announced that it has named Marcy Graham as Vice President, Investor Relations and Corporate Communications. Ms. Graham was previously Executive Director of Investor Relations and Corporate Communications at Ambit Biosciences, where she built the company's investor relations program from their initial public offering to their eventual acquisition. In her role at aTyr, Ms. Graham will spearhead investor relationship management while positioning the company as a global leader in the development of Physiocrine-based medicines to address severe, rare diseases.

aTyr Pharma Seeks Acquisitions

aTyr Pharma Inc. announced an initial public offering of its common stocks and said that, "We may also use a portion of the net proceeds to in-license, acquire, or invest in additional businesses, technologies, products, or assets. Although we have no specific agreements, commitments, or understandings with respect to any in-license or acquisition."

Similar Private Companies By Industry

Company Name Region
Skinetics Biosciences, Inc. United States
AllCells, LLC United States
InterLink Biotechnologies, LLC United States
Avra Medicines, Inc. United States
SG Biofuels, Inc. United States

Recent Private Companies Transactions

Private Placement
March 31, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact aTyr Pharma Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at